Skip to main content
Premium Trial:

Request an Annual Quote

Epic Sciences' Cancer Dx Laboratory Receives CLIA Certification

NEW YORK (GenomeWeb) – Epic Sciences today announced that it has received CLIA certification for its cancer diagnostics laboratory.

The firm's technology platform is for identifying and characterizing rare cells, including circulating tumor cells, to detect cancer and measure the effectiveness of targeted therapies.  

"With the recent move to our expanded facility in San Diego and this initial CLIA certification, we have executed on our next growth phase and continued our commitment to quality laboratory testing to provide accurate, reliable, and timely test results," Murali Prahalad, president and CEO of Epic, said in a statement. "We can now accept clinical samples from 46 states, in addition to accepting clinical samples in Europe and Asia through our [Laboratory Corporation ofAmerica] collaboration."

About a year ago, Epic and LabCorp announced an agreement to accelerate sample processing for Epic's technology in support of European clinical trials. Prahalad added that with today's deal, "Epic can now participate in a greater variety of therapeutic clinical trials as a companion diagnostic partner."

In July 2014, the firm announced the closing of $30 million Series C funding round.